The observed comparable proportion of genomic repeat regions within the TMPRSS2 and ERG breakpoint cluster region to other mesenchymal tumors is an important prerequisite for the design of tumor-specific primers and probes for a highly sensitive therapy monitoring in prostate cancer patients. This evidence concerns the gene ERG and prostate cancer.